Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.57 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.47 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 2/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770640 | 0.90 | EGFR (0.49) | EGFRAURKAAURKBFBP1GRM1 | |
| SCHEMBL4772569 | 0.90 | EGFR (0.50) | EGFRAURKAAURKBINCENPTPX2 | |
| SCHEMBL4765608 | 0.88 | EGFR (0.52) | EGFRAURKAAURKBFBP1GRM1 | |
| SCHEMBL4764395 | 0.88 | EGFR (0.52) | EGFRAURKAAURKBFBP1GRM1 | |
| SCHEMBL4772678 | 0.87 | EGFR (0.55) | EGFRAURKAGRM1CSF1R | |
| SCHEMBL4769376 | 0.86 | BRAF (0.51) | EGFRAURKAAURKBINCENPTPX2 | |
| SCHEMBL7496670 | 0.85 | EGFR (0.62) | EGFRAURKAAURKBFBP1GRM1 | |
| Hydrochloric Acid SCHEMBL4767230 | 0.85 | BRAF (0.50) | EGFRAURKAAURKBINCENPTPX2 | |
| SCHEMBL4764445 | 0.85 | EGFR (0.48) | EGFRAURKAAURKBERBB2ERBB4 | |
| SCHEMBL4767298 | 0.85 | EGFR (0.49) | EGFRAURKAAURKBFBP1GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101560214-A | 4-amino-6-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2009-10-21 | — | — | CN | claimed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | claimed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | claimed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | claimed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
| CN-1538847-A | 4-amino-6-phenyl-pyrrolo [2, 3-d ] pyrimidine derivatives | ��˹��ŵ�� | 2004-10-20 | — | — | CN | claimed |
| US-7390805-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-06-24 | — | — | US | disclosed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-7323469-B2 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | disclosed |
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | BOLD GUIDO | 2007-07-12 | — | — | US | disclosed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | TYMP, DPYD, CCND2 | EGFR 1650/4885AURKA 444/4885AURKB 415/4885 |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, DHPS, TYMP | EGFR 3391/4885AURKA 1206/4885AURKB 964/4885 |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | EGFR 2694/4885AURKA 875/4885AURKB 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.